Cardiovascular monoclonal antibody therapeutic - BioMarin Pharmaceutical
Alternative Names: Cardiovascular Monoclonal antibodies (CV mAB) - BioMarin Pharmaceutical; CV mABLatest Information Update: 23 Apr 2024
At a glance
- Originator BioMarin Pharmaceutical
- Class Cardiovascular therapies; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 23 Apr 2024 Preclinical trials in Cardiovascular disorders in USA (unspecified route) before April 2024 (BioMarin Pharmaceuticals pipeline, April 2024)
- 22 Jun 2023 Early research in Cardiovascular disorders in USA (Parenteral), prior to June 2023 (BioMarin Pharmaceutical pipeline, June 2023)